Inhibitory receptor agonists: the future of autoimmune disease therapeutics?
Journal
Current opinion in immunology
ISSN: 1879-0372
Titre abrégé: Curr Opin Immunol
Pays: England
ID NLM: 8900118
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
15
05
2020
revised:
10
06
2020
accepted:
11
06
2020
pubmed:
4
7
2020
medline:
5
10
2021
entrez:
4
7
2020
Statut:
ppublish
Résumé
Central and peripheral tolerance both contribute to protection against autoimmunity. The pathogenesis of autoimmunity, however, can result from critical deficits or limitations in peripheral and/or central tolerance mechanisms, presenting an opportunity for therapeutic intervention. Recent advances highlight the substantial impact of inhibitory receptors (IRs), which mediate peripheral tolerance, in autoimmunity. Deletion and blockade studies in mice, IR disruption in humans, and correlation with positive disease outcomes all highlight potential clinical benefits of enhancing IR signaling (agonism)-specifically CTLA4, PD1, LAG3, TIM3 and TIGIT-to treat autoimmune disease. Although critical questions remain, IR agonists represent an unappreciated and untapped opportunity for the treatment of autoimmune and inflammatory diseases.
Identifiants
pubmed: 32619929
pii: S0952-7915(20)30064-9
doi: 10.1016/j.coi.2020.06.001
pmc: PMC7744338
mid: NIHMS1605154
pii:
doi:
Substances chimiques
Receptors, Immunologic
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-9Subventions
Organisme : NIAID NIH HHS
ID : F31 AI147638
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI144422
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI089443
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK089125
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI108545
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
Cell Immunol. 2017 Sep;319:3-9
pubmed: 28844471
Arthritis Rheum. 2010 Jul;62(7):1870-80
pubmed: 20506224
J Immunol. 2020 Feb 15;204(4):810-818
pubmed: 31907283
Clin Immunol. 2008 Apr;127(1):78-88
pubmed: 18282810
J Immunol. 2018 Apr 15;200(8):3000-3007
pubmed: 29500245
Arthritis Rheumatol. 2020 Jan;72(1):125-136
pubmed: 31342624
J Clin Invest. 2006 Aug;116(8):2252-61
pubmed: 16886063
J Immunol. 2011 Oct 1;187(7):3493-8
pubmed: 21873518
Mult Scler. 2017 Apr;23(5):686-695
pubmed: 27481207
Nat Rev Immunol. 2008 Jul;8(7):523-32
pubmed: 18566595
Ann Rheum Dis. 2014 Jul;73(7):1393-6
pubmed: 24473674
Front Immunol. 2018 Oct 08;9:2306
pubmed: 30349540
N Engl J Med. 2006 Sep 7;355(10):1018-28
pubmed: 16908486
Nature. 2018 Jun;558(7710):454-459
pubmed: 29899446
Immunity. 1995 Nov;3(5):541-7
pubmed: 7584144
Immunity. 2016 May 17;44(5):955-72
pubmed: 27192563
Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11823-8
pubmed: 16087865
Nat Commun. 2019 Oct 25;10(1):4882
pubmed: 31653839
Sci Immunol. 2017 Mar 31;2(9):
pubmed: 28783703
J Immunol. 2012 Apr 15;188(8):3869-75
pubmed: 22427644
Trends Immunol. 2019 Jun;40(6):511-523
pubmed: 31053497
Clin Immunol. 2006 Feb-Mar;118(2-3):258-67
pubmed: 16386962
Expert Opin Investig Drugs. 2016;25(4):493-9
pubmed: 26878310
J Immunol. 1998 Oct 15;161(8):4058-65
pubmed: 9780176
Nat Immunol. 2019 Nov;20(11):1425-1434
pubmed: 31611702
Rheumatol Int. 2011 Apr;31(4):513-9
pubmed: 20035333
Immunity. 2004 Oct;21(4):503-13
pubmed: 15485628
Nat Immunol. 2016 Mar;17(3):304-14
pubmed: 26829766
Immunity. 1999 Aug;11(2):141-51
pubmed: 10485649
Science. 1995 Nov 10;270(5238):985-8
pubmed: 7481803
Cell Immunol. 2016 Dec;310:27-41
pubmed: 27660198
J Exp Med. 2011 Feb 14;208(2):395-407
pubmed: 21300912
Science. 2008 Oct 10;322(5899):271-5
pubmed: 18845758
J Neuroimmunol. 2007 Jan;182(1-2):124-34
pubmed: 17182110
J Clin Invest. 2020 Jan 2;130(1):480-490
pubmed: 31815738
J Immunol. 2004 Dec 1;173(11):6806-12
pubmed: 15557174
PLoS One. 2014 Aug 14;9(8):e104484
pubmed: 25122007
Gastroenterology. 2012 Jul;143(1):62-69.e4
pubmed: 22504093
Nucleic Acids Res. 2019 Jan 8;47(D1):D1056-D1065
pubmed: 30462303
Int Immunol. 2011 May;23(5):335-44
pubmed: 21521881
J Clin Invest. 2018 Oct 1;128(10):4669-4681
pubmed: 30198907
Drugs. 2017 Jul;77(11):1221-1233
pubmed: 28608166
Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12204-9
pubmed: 11035773
EMBO J. 2007 Jan 24;26(2):494-504
pubmed: 17245433
Nat Med. 2017 May 5;23(5):540-547
pubmed: 28475571
J Immunol. 2019 Jul 1;203(1):48-57
pubmed: 31109955
J Immunol. 2007 Jan 15;178(2):918-25
pubmed: 17202353
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
J Exp Med. 2015 Sep 21;212(10):1603-21
pubmed: 26371185
Nature. 2015 Jul 30;523(7562):612-6
pubmed: 26123020
Immunity. 2016 May 17;44(5):989-1004
pubmed: 27192565
Cancer Res. 2012 Feb 15;72(4):917-27
pubmed: 22186141
Oncotarget. 2017 May 31;8(57):97671-97682
pubmed: 29228642
Nat Rev Immunol. 2002 Jan;2(1):11-9
pubmed: 11908514
J Exp Med. 1998 Feb 2;187(3):427-32
pubmed: 9449722
J Immunol. 2011 Feb 1;186(3):1338-42
pubmed: 21199897
Immunity. 2016 May 17;44(5):1034-51
pubmed: 27192568
Curr Opin Immunol. 2016 Dec;43:74-80
pubmed: 27744240
Transplantation. 2003 Sep 27;76(6):994-9
pubmed: 14508368
Int J Pharm. 2018 Jan 30;536(1):310-317
pubmed: 29217470
J Immunol. 1999 May 15;162(10):5784-91
pubmed: 10229811
J Clin Invest. 2018 Nov 1;128(11):4884-4897
pubmed: 30130253
Nature. 2002 Jan 31;415(6871):536-41
pubmed: 11823861
Cell Metab. 2020 Jan 7;31(1):46-61
pubmed: 31839487
Sci Immunol. 2016 Nov;1(5):
pubmed: 28664195
Lancet. 2011 Jul 30;378(9789):412-9
pubmed: 21719096
Nat Immunol. 2017 Jun 20;18(7):716-724
pubmed: 28632714
Autoimmun Rev. 2013 Oct;12(12):1171-6
pubmed: 23851140
Biomed Res Int. 2014;2014:215763
pubmed: 24605322
Gut. 2015 Feb;64(2):260-71
pubmed: 24902766
Genes Dis. 2018 Oct 18;5(4):302-303
pubmed: 30591930
Cell. 2019 Jan 10;176(1-2):334-347.e12
pubmed: 30580966
EBioMedicine. 2017 Aug;22:44-57
pubmed: 28750861